Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name (Ascending) Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00310-9500-01 00310-9500 Capivasertib TRUQAP 160.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Nov. 16, 2023 In Use
00310-9501-01 00310-9501 Capivasertib TRUQAP 200.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Nov. 16, 2023 In Use
72730-0101-01 72730-0101 infigratinib TRUSELTIQ 125.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral May 28, 2021 In Use
72730-0202-01 72730-0202 infigratinib TRUSELTIQ 75.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral May 28, 2021 In Use
72730-0506-01 72730-0506 infigratinib TRUSELTIQ 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral May 28, 2021 In Use
72730-0111-01 72730-0111 infigratinib TRUSELTIQ 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral May 28, 2021 In Use
51144-0002-12 51144-0002 Tucatinib TUKYSA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor HER2 Oral April 17, 2020 In Use
51144-0002-60 51144-0002 Tucatinib TUKYSA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor HER2 Oral April 17, 2020 In Use
51144-0001-60 51144-0001 Tucatinib TUKYSA 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor HER2 Oral April 17, 2020 In Use
00078-0671-19 00078-0671 Lapatinib TYKERB 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Aug. 3, 2016 In Use

Found 10,000 results in 10 millisecondsExport these results